Cargando…

The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson’s disease: A systematic review and meta-analysis

BACKGROUND: Parkinson’s Disease (PD) is a progressive neurodegenerative condition associated with significant morbidity. Currently, there are limited pharmacological options and none of the therapies available are disease-modifying. This systematic review and meta-analysis considers a novel drug cla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dahiya, Simran, Tisch, Stephen, Greenfield, Jerry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804263/ https://www.ncbi.nlm.nih.gov/pubmed/35128376 http://dx.doi.org/10.1016/j.prdoa.2022.100133

Ejemplares similares

An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke
por: Zhang, Huinan, et al.
Publicado: (2016)

GLP-1 and GIP receptor agonists in the treatment of Parkinson’s disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies
por: Vaccari, Carolina, et al.
Publicado: (2021)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis
por: Piccoli, Giovana Fagundes, et al.
Publicado: (2021)

Targeting GLP-1 receptor trafficking to improve agonist efficacy
por: Jones, Ben, et al.
Publicado: (2018)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

Emerging Nondopaminergic Medications for Parkinson’s Disease: Focusing on A(2A) Receptor Antagonists and GLP1 Receptor Agonists
por: Shang, Pei, et al.
Publicado: (2021)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond
por: Ryan, Donna, et al.
Publicado: (2015)

GLP-1 receptor agonists: an updated review of head-to-head clinical studies
por: Trujillo, Jennifer M., et al.
Publicado: (2021)

Robust anti‐obesity and metabolic effects of a dual GLP‐1/glucagon receptor peptide agonist in rodents and non‐human primates
por: Henderson, S. J., et al.
Publicado: (2016)

GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
por: Rezaei, Shahla, et al.
Publicado: (2021)

GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata
por: Goggins, Michael
Publicado: (2012)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chia, Chee W, et al.
Publicado: (2009)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff, Lisa M, et al.
Publicado: (2010)

GLP-1 receptor agonist ameliorates experimental lung fibrosis
por: Fandiño, Juan, et al.
Publicado: (2020)

Medullary Carcinoma of Thyroid Due to GLP-1 Receptor Agonist
por: Vemula, Hasitha, et al.
Publicado: (2021)

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
por: Monti, Giulia, et al.
Publicado: (2022)

GLP-1 receptor agonist as a modulator of innate immunity
por: Chen, Jun, et al.
Publicado: (2022)

Effects of GLP-1 receptor agonists on neurological complications of diabetes
por: García-Casares, Natalia, et al.
Publicado: (2023)

Novel agonist and antagonist radioligands for the GLP‐2 receptor. Useful tools for studies of basic GLP‐2 receptor pharmacology
por: Gadgaard, Sarina, et al.
Publicado: (2022)

The GLP‐1/GIP dual‐receptor agonist DA5‐CH inhibits the NF‐κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP‐1 single‐receptor agonist NLY01
por: Lv, MiaoJun, et al.
Publicado: (2021)

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
por: Prasad-Reddy, Lalita, et al.
Publicado: (2015)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
por: Kawanami, Daiji, et al.
Publicado: (2020)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
por: Rojano Toimil, Alba, et al.
Publicado: (2021)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
por: Balena, R, et al.
Publicado: (2013)

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
por: Karagiannis, Thomas, et al.
Publicado: (2022)

Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?
por: Amouyal, Chloé, et al.
Publicado: (2016)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease
por: Zhang, Zijuan, et al.
Publicado: (2023)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
por: Lee, Jinmi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2l9kis9evlkfdb670bv4ipdbqo